Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with full-year revenue totaling $109.4 million, reflecting strong performance [3][14] - Adjusted EBITDA for Q4 2025 was $12 million, and for the full year, it was $24.3 million, indicating more than doubled year-over-year growth [3][16] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [14][15] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [16] Business Line Data and Key Metrics Changes - The company saw solid performance across both established clients and a growing number of mid-tier and long-tail life science companies, which are viewed as attractive for future growth [3][4] - Average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups [18] Market Data and Key Metrics Changes - The company is experiencing a broader pause in spending across its client base, with clients adopting a more conservative approach due to market shifts and negotiations related to Most-Favored-Nation pricing [4][22] - The net revenue retention rate remained strong at 116%, indicating effective customer retention despite market challenges [18] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue stream [89] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [7] - The company aims to leverage AI as a tool for efficiency, enhancing marketing execution rather than being disrupted by it [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that current market softness is temporary and expects normalization in client spending in the coming months [5][22] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expected revenue between $109 million and $114 million [5][18] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail segments of the market [5][46] Other Important Information - The company ended 2025 with cash and short-term investments totaling $23.4 million, up from $13.4 million in 2024, despite paying down $8 million in principal [17] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [11][12] Q&A Session Summary Question: Are you seeing conservatism across all clients or just those in MFN negotiations? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [22] Question: Are there nuances between DTC and HCP marketing pressures? - Management indicated that both DTC and HCP marketing are experiencing similar pressures from clients [23] Question: What drove the high gross margins in Q4, and why might they not be sustainable? - Management explained that a favorable mix of channel partners contributed to high margins, but they expect margins to normalize to the mid-60% range in 2026 [25][26] Question: How is AI impacting operations? - Management sees AI as an enabler for efficiency, allowing clients to reallocate spending from content creation to commercial execution [29][75] Question: What is the current percentage of revenue under contract? - Management indicated they are running approximately 15%-20% behind last year's contracted revenue due to shorter contract durations [35][36] Question: How does the guidance for 2026 account for managed services? - The guidance includes very little from managed services, which is considered an episodic solution [40] Question: What strategies are in place to capture mid-tier and smaller manufacturers? - The company is positioned to fill gaps for mid-tier clients lacking extensive marketing resources, leading to faster-than-expected growth in this segment [45][46]

Financial Data and Key Metrics Changes - In Q4 2025, Adjusted EBITDA increased by $2.2 million or 17.1% to $15.2 million compared to $13 million in Q4 2024 [4] - Q4 revenue was $90.9 million, a 4% decrease from the prior year, but excluding flight equipment sales, revenue increased by 9.8% [4][5] - For the full year 2025, total revenue was $335.3 million, a decrease of $9.8 million or 2.8% year-over-year, primarily due to fewer flight equipment sales [6] - Full year Adjusted EBITDA increased by $12.8 million to $46.1 million, up 38.2% year-over-year [7][18] Business Line Data and Key Metrics Changes - Asset Management revenue in Q4 declined approximately 11.1% year-over-year to $56.9 million due to fewer flight equipment sales [14] - Excluding flight equipment sales, Asset Management segment revenue increased by 47.3% for the full year, supported by strong inventory levels and demand [15] - TechOps revenue in Q4 increased by 10.7% to $34 million, driven by higher sales in aerostructures and landing gear MROs [15] - For the full year, TechOps revenue declined by 4.5% to $123.7 million, primarily due to lower on-airport MRO activity, but gross margin improved to 25.6% from 16.6% [16] Market Data and Key Metrics Changes - The company ended 2025 with $364 million of inventory, including approximately $150 million ready for deployment in the USM channel [28] - The win rate for feedstock acquisition was 4.8% in Q4 2025, down from 17.2% in Q4 2024, indicating a hyper-competitive market [7][8] Company Strategy and Development Direction - The company aims to mitigate earnings volatility by growing more recurring and predictable parts of the business, including expanding USM sales and leasing [11] - Strategic adjustments in MRO facilities are expected to contribute significantly to profitability in 2026 [9] - The company is focused on marketing its Enhanced Flight Vision System, AerAware, to both commercial and governmental customers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving substantial growth in 2026, supported by efficiency initiatives and a strong balance sheet [12][19] - The company anticipates steady incremental improvements as new revenue streams ramp up and efficiency initiatives continue to gain traction [19] Other Important Information - The company received FAA approval to overhaul Boeing 737 MAX and 787 landing gear, expanding its capabilities [10] - The AerSafe product line is expected to see significant sales in 2026 due to compliance deadlines, with a backlog already exceeding last year's total sales [48] Q&A Session Summary Question: Feedstock acquisition goals and inventory monetization - Management anticipates a lower level of feedstock purchases in 2026 compared to 2025 due to a hyper-competitive market [22][23] - The company has ample inventory to support growth without needing to purchase as much feedstock as last year [27][28] Question: Impact of GTF normalization and AerSafe deadline - Management does not expect GTF normalization in 2026, as engine returns are anticipated to extend into 2027 [31] - AerSafe sales are expected to peak in 2026, with ongoing efforts to develop new engineered products to maintain revenue [49]

Financial Data and Key Metrics Changes - Owlet achieved record annual revenue of $105.7 million for 2025, representing a 35.4% increase over 2024 [10][24] - Q4 2025 revenue was $26.6 million, up 29.6% year-over-year, driven by growth across the Dream product suite and Owlet360 subscription [10][23] - Full year 2025 gross margin was a record 50.6%, despite a 510 basis point impact from tariffs [10][24] - Adjusted EBITDA for Q4 was $0.1 million, down from $0.5 million in Q4 2024, while full year Adjusted EBITDA reached $2 million, a $3.8 million improvement over 2024 [10][11][25] Business Line Data and Key Metrics Changes - The Owlet360 subscription service crossed 110,000 paying subscribers, contributing to the company's long-term business strategy [5][17] - Dream Sock and Duo demonstrated strong domestic year-over-year sell-through at 9% and 53% respectively, indicating robust demand [12] - The introduction of the Dream Sight camera is expected to enhance customer lifetime value (LTV) and drive subscriber growth [7][11] Market Data and Key Metrics Changes - Owlet expanded its market share in baby monitors to 41% in Q4 2025, a 24% increase compared to Q4 2024 [13] - International revenue for Q4 reached $3.9 million, totaling $19.2 million for the year, a 27% increase over 2024 [14] - Strong sell-through was observed in international markets, with the U.K. up 58%, France up 41%, and the Nordics up 80% versus Q4 2024 [15] Company Strategy and Development Direction - The company aims to drive global adoption of Dream Sock, expand the Owlet360 subscription platform, grow healthcare channels, and launch the Owlet telehealth platform [11][19] - Owlet is focusing on integrating AI across its platforms to enhance competitive edge and support parents [18] - The company is positioned to redefine modern parenting by establishing a comprehensive pediatric health monitoring platform [65] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong performance and growth into 2026, despite challenges such as tariffs and macroeconomic pressures [11][30] - The company anticipates another record year of growth in 2026, with revenue expected to be in the range of $126 million to $130 million, representing a 19%-23% increase over 2025 [28][30] - The first quarter of 2026 is expected to be the lowest revenue contributor due to seasonality, but management remains optimistic about long-term demand [33][30] Other Important Information - The company simplified its capital structure and strengthened its balance sheet through a successful equity offering [8] - Owlet's telehealth platform is expected to launch in the second half of 2026, enhancing care quality and patient outcomes [20][47] Q&A Session Summary Question: Guidance for Q1 and revenue expectations - Management noted that Q1 is historically the lightest revenue contributor and that current macroeconomic conditions have influenced consumer spending [33][34] Question: Generative AI insights and their impact - The company sees a significant opportunity to leverage AI for personalized parenting support and to enhance subscription features [36] Question: International expansion and subscription progress - Management expects international revenue to begin in the first half of the year and is excited about the potential for subscription growth in new markets [41] Question: Go-to-market strategy for telehealth offering - The telehealth platform will be an upsell to Owlet360, with a focus on refining the user experience before the full launch [47] Question: Churn rate for Owlet360 subscribers - Management reported positive trends in subscriber growth and retention rates, with plans to share more data in future calls [50]

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported revenue of $161 million, an increase of 849% compared to the previous year, with a loss from operations of $20 million, down by $71 million [17][18] - Non-GAAP Adjusted EBITDA for 2025 was $16 million, an increase of $74 million year-over-year, with Q4 2025 showing almost $8 million in Adjusted EBITDA [10][18] - Cash flow from operations turned positive in Q4 2025, generating $20 million, and cash equivalents increased to $117 million at year-end, a $9 million increase from Q3 [17][18] Business Line Data and Key Metrics Changes - Gevo North Dakota produced a record-setting low-carbon ethanol volume of approximately 69 million gallons in 2025, with a carbon capture of 173,000 metric tons [10][22] - The company plans to expand capacity at Gevo North Dakota to 75 million gallons per year and increase carbon sequestration to at least 200,000 metric tons annually [10][23] Market Data and Key Metrics Changes - The company reported that about 80% of carbon benefits were attached to ethanol sold into low-carbon fuel markets, with an inventory of approximately 30,000 tons of Carbon Dioxide Removal credits by the end of Q4 [12] - The customer base for CDR credits has expanded to include companies like PayPal and Bank of Montreal, indicating a growing market demand [12] Company Strategy and Development Direction - The company is focused on its Alcohol-to-Jet (ATJ) project, Project North Star, which aims to deliver $150 million in Adjusted EBITDA annually once constructed [13][14] - Gevo is pursuing a franchise model for deploying synthetic aviation fuel globally, leveraging its intellectual property and business system [14][15] - The company is also exploring acquisitions that are strategically aligned with its platform to further scale Adjusted EBITDA [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve a target of approximately $40 million in annualized non-GAAP Adjusted EBITDA in 2026, with a focus on maintaining positive operating cash flow [18][21] - The management highlighted the importance of the carbon business and its potential for growth, emphasizing the need to monetize carbon effectively [78] Other Important Information - The company has a conditional commitment from the U.S. Department of Energy for a loan guarantee to finance the construction of the ATJ plant [16] - Management noted that the transition to new leadership will not disrupt the company's strategic direction, with Paul Bloom set to take over as CEO [5][8] Q&A Session Summary Question: Changes in CI calculations - Management confirmed that changes to the CI score are expected to reduce it by six to seven points, potentially generating an incremental $0.10 per gallon in 2026 [29] Question: ATJ project financing and FID - Management indicated that while the DOE extension is important, they are also working with other parties to secure financing for the ATJ project [31][34] Question: Path to $40 million in EBITDA - Management outlined that the trajectory to reach $40 million in EBITDA involves leveraging existing assets and carbon monetization strategies [41][43] Question: Potential acquisitions - Management is looking for similar assets to Gevo North Dakota that can benefit from their expertise and business model [44][46] Question: CDR pricing outlook - Management noted that pricing in the voluntary CDR markets typically ranges from $100 to $300 per ton, with competition increasing from low-carbon fuel markets [99]

Financial Data and Key Metrics Changes - Omada Health achieved 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][30] - The total member count increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - GAAP net income was positive for the first time in Q4 at $5 million, improving from a net loss of $8 million in Q4 2024 [30][35] - Adjusted EBITDA for the full year was $6 million, a significant improvement from a loss of $29 million in 2024 [30][35] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew over 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][68] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, adding more than 100,000 in 2025 [10][19] - The introduction of the GLP-1 prescribing capability and the new GLP-1 Flexcare option are expected to enhance the company's service offerings and revenue potential [11][22] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million eligible lives [18] - The total addressable market for Omada's services is estimated at over $138 billion, with current penetration below 10% [19] - Government initiatives, such as the PREVENT DIABETES Act, are expected to enhance the recognition of virtual care solutions, expanding access to quality care [19][20] Company Strategy and Development Direction - Omada's strategy focuses on innovation, effective programs, and a multi-condition platform to address cardiometabolic health [20][25] - The company aims to balance growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16][34] - Investments in AI and technology are expected to enhance member experience and operational efficiency [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a clear plan for growth, driven by market demand for chronic care solutions [4][5] - The company anticipates continued strong performance, with 2026 revenue guidance in the range of $312 million to $322 million, reflecting 22% growth over 2025 [37][38] - Management highlighted the importance of leveraging unique data sets and AI to improve care personalization and operational efficiency [65] Other Important Information - Omada's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, indicating strong operational leverage [31][32] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [37] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business performance without significant contributions from new opportunities, indicating a conservative approach [42][46] Question: How is the GLP-1 FlexCare program structured? - The GLP-1 FlexCare program provides a structured model for employers to support employees with clinical evaluation and prescribing, while allowing employees to purchase medications out-of-pocket [56] Question: What are the growth prospects for diabetes and hypertension programs? - Management noted that growth in diabetes and hypertension programs is strong, with both growing at rates similar to overall revenue growth, reflecting the integrated cardiometabolic approach [66][68]

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, reflecting a 53% increase compared to the previous year [6][26] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [24] - Net operating loss for the quarter was $3.3 million, a significant decrease from $7.6 million in the prior year [25] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [25] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the full year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [26] - Research and development expenses decreased by $2.7 million for the year, mainly due to the closeout of clinical trial expenses related to nelitolimod [27] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [28] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market, including thyroid and uterine artery embolization, represents a $2.3 billion opportunity [15][16] - The introduction of the CMS HCPCS code C8004 expanded coverage for simulation or mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [16] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to nearly double the commercial footprint [9][10] - The company is investing in foundational clinical studies to validate the Pressure-Enabled Drug Delivery (PEDD) platform, which is expected to drive growth in 2027 and beyond [9] - The product portfolio is expanding from two core products at the beginning of 2025 to seven differentiated offerings by 2026, enhancing sales productivity [12] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed revenue guidance for 2026 in the range of $60 million to $62 million, with growth expected to be weighted towards the second half of the year [9][22] - The company anticipates that the significant investment in the sales force will lead to stronger productivity and revenue growth exiting 2026 [10] - Management emphasized the importance of clinical data releases in driving adoption of new applications, particularly in non-liver areas [33][60] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [8][30] - The company is awaiting FDA clearance for the TriNav Advance product, which is expected to enhance therapeutic delivery and expand market opportunities [15][49] Q&A Session Summary Question: Contribution to growth in 2026 from liver versus non-liver - Management indicated that liver will still be the majority of revenue in 2026, but expects meaningful progress in new applications tied to data releases in the second half of the year [33] Question: Balancing growth cadence and EBITDA pathway - Management is not providing specific timing on cash flow or adjusted EBITDA breakeven but is focused on investments to scale the company meaningfully [34][35] Question: Details on the sales organization structure after investments - Management confirmed that the commercial organization will be significantly expanded, including adding a layer of management to improve sales effectiveness [39][40] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from TriNav XP and TriNav Advance, which are expected to enhance mapping capabilities [46][48] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [52][56] Question: Long-term opportunities for TriNav in liver versus non-liver - Management highlighted that liver will remain a significant component of sales, but sees substantial growth potential in thyroid artery embolization and other new applications [60][62]

Financial Data and Key Metrics Changes - The company reported a debt-free status and strengthened working capital for the full year 2025, with improved royalties when adjusted for one-time licensee events [4][7] - A private placement of $1.1 million was completed at $1 per share, indicating a strategic move to reinforce the balance sheet [5][7] Business Line Data and Key Metrics Changes - The automotive pipeline has seen meaningful expansion, with Ferrari and Cadillac adopting SPD-SmartGlass, and Mercedes showcasing SPD in a concept vehicle [3][12][14] - The transition of Ferrari's business to a new licensee, Isoclima, was successfully executed, maintaining continuity despite challenges [10][11] Market Data and Key Metrics Changes - The architectural retrofit market is identified as a significant opportunity, with initial projects already underway [16][17] - The company has broadened its automotive pipeline, with high-volume quotations on four models and specialty programs with potential annual volumes in the tens of thousands [15][29] Company Strategy and Development Direction - The company is focusing on expanding its automotive and architectural retrofit initiatives, with a strong emphasis on new product development and capital positioning [3][4] - The strategy includes addressing customer feedback for SPD technology, particularly in aesthetics and performance, to broaden market appeal [15][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational continuity of SPD production and program execution despite Gauzy's restructuring efforts [19][25] - The company anticipates meaningful revenue growth from automotive programs as integration progresses, with a broader pipeline than ever before [26][29] Other Important Information - Gauzy's French subsidiaries are undergoing a rehabilitation process, but this does not affect the overall production capabilities in Germany and Israel [8][19] - The company remains in close contact with Gauzy, ensuring that production and program execution continue despite the challenges faced [10][25] Q&A Session Summary Question: Concerns about Gauzy's French rehabilitation proceeding - Management indicated that the situation is improving and that the rehabilitation process applies only to Gauzy's French subsidiaries, with production continuing elsewhere [18][19] Question: Impact of war on operations - Management acknowledged disruptions due to the war but noted that operations are adapting and continuing [20][21] Question: Timing of capital raise and stock price concerns - Management clarified that the capital raise was necessary due to unpaid receivables and supply disruptions, emphasizing the importance of liquidity for executing the business plan [60][75] Question: Future revenue growth expectations - Management stated that automotive integration takes time, but confidence is high due to validated technology across multiple OEMs [26][29] Question: Interest from Ferrari in expanding SPD roofs - Management confirmed that Ferrari has expressed interest in expanding SPD roofs to other models [90]

Financial Data and Key Metrics Changes - Revenues for Q4 2025 increased to $75.4 million, up from $73 million in Q4 2024, representing a growth of 5.6% on a comparable basis [4][5] - Adjusted EBITDA for Q4 2025 rose to $10.7 million, compared to $10.4 million in Q4 2024, with a 23% increase when excluding one-time items from the previous year [4][5] Business Line Data and Key Metrics Changes - At American Place, revenues increased by 11% to $32 million in Q4 2025, with adjusted property EBITDA rising 29% to $8.7 million [5] - For the full year, American Place's revenues and adjusted property EBITDA rose to $124 million and $34.3 million, reflecting increases of 13% and 17% respectively [5] - Chaminade's revenue growth was 5% in the second half of 2025 compared to the same period in 2024, with adjusted property EBITDA improving significantly [8] Market Data and Key Metrics Changes - The company operates in a market that remains under-penetrated, with the permanent American Place facility expected to achieve a run rate EBITDA of about $100 million [6][7] - The closest competitor generates approximately $500 million in gaming revenue annually, indicating significant market potential for the company [7] Company Strategy and Development Direction - The company is focused on enhancing its management team and marketing efforts to drive growth, particularly at Chaminade and Silver Slipper [8][12] - Plans for the permanent American Place Casino are progressing, with foundation drawings expected to be completed soon, allowing for construction to begin [13][14] - The company aims to improve customer loyalty and expand its market reach through targeted marketing strategies [59][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of American Place, citing its strategic location and market dynamics [6][7] - The company is optimistic about revenue growth in 2026, particularly at American Place and Chaminade, despite some operational challenges [10][28] - Management acknowledged the need for ongoing improvements in operational efficiency and customer service to enhance profitability [25][76] Other Important Information - The company had approximately $51 million in liquidity at the end of the quarter, positioning it well for cash flow generation [12] - A recent amendment to the revolving credit facility extended its maturity date to August 15, 2027, providing financial flexibility [13] Q&A Session Summary Question: What is the outlook for Chaminade given recent performance? - Management noted that previous promotional strategies had inflated revenues without corresponding profit, but new management is expected to drive better results moving forward [19][20] Question: Have there been any signs of re-acceleration in Q1 2026? - Management indicated that there has been some improvement in revenue despite renovation disruptions, suggesting a positive trend [22] Question: What is the status of the Indiana bill regarding Rising Sun? - Management highlighted the evolving nature of the legislation and expressed cautious optimism about the potential for relocation, while continuing to generate profits from Rising Sun [36][38] Question: Can you provide an update on the financing for American Place? - Management confirmed that they are in discussions for financing that will not involve equity sales and will also address existing debt refinancing [42][46] Question: What is driving the growth at Waukegan? - Management credited a strong team and effective marketing strategies for the continued double-digit growth in the region [121][124]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported record revenue of $106.2 million, exceeding Wall Street expectations, with a year-over-year growth of 5.9% and a sequential growth of 1.9% [4][25] - Full year 2025 revenue reached $411.8 million, representing a 17.5% year-over-year growth, with non-GAAP EBITDA of $53.8 million [4][25] - Non-GAAP EBITDA for Q4 was $13.7 million, or 12.9% of revenue, which was at the higher end of the guidance range [25][31] Business Line Data and Key Metrics Changes - AI revenue grew by 9% over Q3 and accounted for 25% of overall revenue in Q4, with full year AI revenue exceeding $90 million, marking a 30% year-over-year growth [5][4] - The retail vertical contributed 28.7% of total revenues in Q4, with a sequential increase of 5.3% but a year-over-year decline of 6.9% [26] - The technology, media, and telecommunications (TMT) vertical accounted for 28.3% of total revenues, showing a strong year-over-year growth of 27.5% [27] - The finance vertical represented 22.9% of total revenues, growing 5% year-over-year, driven by demand from fintech and large banks [27] Market Data and Key Metrics Changes - The company noted a significant increase in partner influence revenue, which exceeded 19% of total revenue in 2025, indicating strong market positioning [9] - The company is prioritizing investments in technology, financial services, and manufacturing sectors, where customized AI solutions are in high demand [7][8] Company Strategy and Development Direction - The company is focusing on AI-driven solutions and platforms, aiming to transition from traditional service models to outcome-based engagements [24][70] - The introduction of proprietary platforms like the Merchandising Experience Platform (MXP) and the bitemporal data platform (XDB) is expected to enhance revenue generation and operational efficiency [19][20] - The company is committed to M&A as a strategic priority to enhance capabilities and geographic presence, particularly in the AI sector [33][94] Management's Comments on Operating Environment and Future Outlook - Management expressed a bullish outlook for 2026, anticipating continued growth in AI revenue and a strong pipeline of projects across various verticals [34][56] - The company acknowledged the impact of currency fluctuations on EBITDA and gross margins but remains optimistic about margin expansion through operational efficiencies and AI-driven solutions [31][92] Other Important Information - The total headcount at the end of Q4 was 4,961, with a slight decrease from the previous quarter but an increase from the previous year [28] - The company is experiencing a shift towards custom-built software solutions as clients seek more tailored approaches in response to market pressures [50][52] Q&A Session All Questions and Answers Question: Can you discuss the nature of AI projects moving into production at scale? - Management highlighted that clients are transitioning from small development projects to full-scale implementations, leveraging proprietary platforms to enhance solution delivery speed and affordability [39][41] Question: What is the outlook for custom-built software in the current market? - Management noted an increased demand for custom-built solutions as clients seek to reduce costs and improve efficiency, benefiting from AI-native environments [50][52] Question: Can you elaborate on the growth outlook for the year and the factors driving it? - Management indicated a robust pipeline of AI-related projects, particularly in technology and financial sectors, and emphasized the importance of seasonal trends in revenue growth [72][76]

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported revenue of $161 million, a significant increase of 849% compared to the previous year, with a loss from operations of $20 million and non-GAAP Adjusted EBITDA of $16 million [17][18] - In Q4 2025, the company achieved positive cash flows from operations, generating $20 million during the period, and increased cash equivalents and restricted cash to $117 million at year-end, a $9 million increase from Q3 [17][18] - The company has recorded three consecutive quarters of positive non-GAAP Adjusted EBITDA, with nearly $8 million in Q4 [10][18] Business Line Data and Key Metrics Changes - Gevo North Dakota produced a record-setting low carbon ethanol volume of approximately 69 million gallons in 2025, while capturing 173,000 metric tons of carbon dioxide [10][22] - The company plans to expand capacity at Gevo North Dakota to 75 million gallons per year and increase carbon sequestration to at least 200,000 metric tons annually [10][23] Market Data and Key Metrics Changes - The company has built an inventory of roughly 30,000 tons of Carbon Dioxide Removal credits (CDRs) by the end of Q4 to meet future demand from spot and contract sales [12] - The customer base for CDR credits has expanded to include companies like PayPal and Bank of Montreal, indicating a growing market demand [12] Company Strategy and Development Direction - The company is focused on its Alcohol-to-Jet (ATJ) growth platform, with Project North Star anticipated to deliver $150 million in Adjusted EBITDA per year once constructed [13][14] - Gevo is pursuing a franchise model to deploy similar plants globally, leveraging its intellectual property and business system [14][15] - The company aims to reach Final Investment Decision (FID) on the ATJ project in 2026, with a conditional commitment from the U.S. Department of Energy for a loan guarantee [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve an annualized non-GAAP Adjusted EBITDA of about $40 million and maintain neutral to positive operating cash flow in 2026 [18][21] - The management highlighted the importance of monetizing carbon credits and the potential for significant growth in the carbon market as a key opportunity for the company [78][79] Other Important Information - The company has successfully integrated the Red Trail Energy assets, which has transformed its operations and financial performance [9][10] - Management emphasized the importance of proven technologies and experienced engineering teams in the development of the ATJ-30 project, differentiating it from other industry projects [86][87] Q&A Session Summary Question: Changes in CI calculations and their impact - Management discussed the expected reduction in CI score by 6 to 7 points due to changes in guidance, which could generate an incremental $0.10 per gallon in 2026 [29] Question: Financing and FID for ATJ-30 - Management confirmed that while the DOE loan guarantee would accelerate the project, they are also exploring other financing options [50][51] Question: Path to $40 million in EBITDA - Management outlined that the trajectory to reach $40 million in EBITDA involves leveraging existing assets and carbon monetization strategies [41][43] Question: Potential acquisitions - Management indicated they are looking for similar assets to Gevo North Dakota that can be integrated into their business model [44][47] Question: Pricing in voluntary CDR markets - Management noted that pricing for voluntary CDRs typically ranges from $100 to $300 per ton, with the company positioned as a top supplier in the market [98][99]